Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: DCVax, Northwest Biotherapeutics.

Keith L Knutson1

  • 1University of Washington, Tumor Vaccine Group, Seattle 98195, USA. kknutson@u.washington.edu

Current Opinion in Molecular Therapeutics
|September 12, 2002
PubMed
Summary

Northwest Biotherapeutics is developing DCVax, a dendritic cell-based immunotherapy, for various cancers. Clinical trials are underway for DCVax-Prostate, DCVax-Brain, and DCVax-Lung, targeting multiple malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of tumor-associated antigens with multi-cancer therapeutic potential.

Frontiers in immunology·2026
Same author

Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer.

Journal for immunotherapy of cancer·2026
Same author

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Prognostic Significance, Predictive Value, and Emerging Directions for Clinical Implementation.

Cancers·2026
Same author

Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy.

Frontiers in immunology·2026
Same author

A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

A vaccination strategy to prevent coxsackie virus B3-induced development of pancreatic cancer.

JCI insight·2025

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Dendritic cell-based immunotherapy represents a novel approach to cancer treatment.
  • Northwest Biotherapeutics is developing DCVax, an active immunization platform, for multiple cancer types.

Purpose of the Study:

  • To summarize the development status and clinical trial progress of DCVax for various malignancies.
  • To highlight the personalized nature of the DCVax platform in cancer treatment.

Main Methods:

  • DCVax platform utilizes purified tumor-specific antigens or tumor cell extracts tailored to individual cancer types.
  • Clinical trials, including Phase I/II, II, and III, are being conducted for different DCVax formulations (Prostate, Brain, Lung).

Main Results:

  • Phase I/II trials for DCVax-Prostate are complete, with Phase III trials initiated.
  • DCVax-Brain is currently in Phase II clinical trials.
  • DCVax-Lung has received FDA approval for Phase I clinical trials.

Conclusions:

  • DCVax is a promising dendritic cell-based immunotherapy platform with ongoing clinical development across several cancer types.
  • The platform's personalized approach and active immunization strategy warrant continued investigation in oncology.

Related Experiment Videos